Xiaoyu Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyu Hu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Shenghao Li
Department of Integrated Traditional Chinese and Western Medicine Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Clinical Medical College, Chengdu University of Traditional Chinese Medicine, No. 37 Shi-er-qiao Road, Chengdu, 610075, Sichuan Province, China
21 shared publicationsLiyuan Hao
Clinical Medical College, Chengdu University of Traditional Chinese Medicine, No. 37 Shi-er-qiao Road, Chengdu, 610075, Sichuan Province, China; Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, 610072, Sichuan Province, China
19 shared publicationsJiali Deng
School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
6 shared publicationsNa Li
Clinical Medical College, Chengdu University of Traditional Chinese Medicine, No. 37 Shi-er-qiao Road, Chengdu, 610075, Sichuan Province, China; Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, 610072, Sichuan Province, China
5 shared publications- Junli Zhang
Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, People’s Republic of China
4 shared publications Fei Yu
Clinical Medical College, Chengdu University of Traditional Chinese Medicine, No. 37 Shi-er-qiao Road, Chengdu, 610075, Sichuan Province, China; Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, 610072, Sichuan Province, China
3 shared publications
Latest Publications
- 13 November 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 120885
Novel mechanism of Guizhi Jia Huangqi decoction disrupting HBV lifecycle via cAMP/PKC/PKB axis beyond NTCP blockade
- 13 November 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 120885
Novel mechanism of Guizhi Jia Huangqi decoction disrupting HBV lifecycle via cAMP/PKC/PKB axis beyond NTCP blockade
- Open Access
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1617604
Zuojin capsule improves T cell exhaustion and tumor immune microenvironment of hepatocellular carcinoma through the mTOR-eIF4E/p70S6K-CDK1 pathway
Background & Aims: Hepatocellular carcinoma (HCC) is a major health concern. T cell exhaustion (Tex), a state of T cell dysfunction characterized by reduced effector function and increased expression of inhibitory receptors. This study aimed to explore the mechanism by which Zuojin capsule (ZJC, Coptidis Rhizoma and Evodiae Fructus) treats HCC and improves Tex.Methods: To identify HCC-related and Tex-associated targets, two HCC expression microarray datasets were integrated. Targets related to Tex were retrieved from GeneCards and Online Mendelian Inheritance in Man (OMIM) databases. Active compounds in ZJC were screened. A protein-protein interaction (PPI) network of overlapping targets was constructed using STRING to identify core functional modules. To verify the anti-proliferative effect of ZJC on HCC cells, the CCK-8 assay was performed to detect the viability of Hep3B and HepG2.2.15 cells treated with gradient concentrations of ZJC. Western Blot analysis was conducted to measure the protein expression levels of key molecules. Immunohistochemical (IHC) staining was used to assess the proliferation index of tumor cells, the infiltration of immune cells, and the expression of immune-related markers.Results: HCC-related genes, Tex targets, and ZJC targets were identified through bioinformatics analysis, 136 overlapping targets were obtained. ZJC inhibited Hep3B/HepG2.2.15 cell proliferation with IC50 values of 310 μg/mL and 530 μg/mL, respectively. The pathway analysis conducted using DAVID revealed that the intersecting targets were mainly enriched in the mTOR signaling pathway and the transcriptional regulation process. H22 xenografts were treated with ZJC or anti-PD-1 to evaluate tumor growth and immune responses. ZJC suppressed HCC cell proliferation and reduced the expression of Ki67. Mechanistically, it downregulated phosphorylated mTOR (p-mTOR), p-eIF4E, and p-p70S6K, and this downregulated state could be reversed by the restoration of mTOR activators. ZJC reduced the expression of cyclin-dependent kinase 1 (CDK1). In HCC tissues, M1 macrophages were reduced, while M2 macrophages and exhausted T cells were accumulated. ZJC treatment inhibited tumor growth and modulated immune infiltration. Additionally, ZJC and anti-PD-1 promoted the expression or aggregation of CD8-positive cells. In addition, the control group showed relatively high positive staining for CD163, whereas ZJC and anti-PD-1 inhibited the expression or aggregation of CD163-positive cells.Conclusion: ZJC exerts dual anti-tumor effects by inhibiting the mTOR-eIF4E/p70S6K-CDK1 pathway and remodeling the immunosuppressive microenvironment of HCC.
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1617604
Open AccessZuojin capsule improves T cell exhaustion and tumor immune microenvironment of hepatocellular carcinoma through the mTOR-eIF4E/p70S6K-CDK1 pathway
Background & Aims: Hepatocellular carcinoma (HCC) is a major health concern. T cell exhaustion (Tex), a state of T cell dysfunction characterized by reduced effector function and increased expression of inhibitory receptors. This study aimed to explore the mechanism by which Zuojin capsule (ZJC, Coptidis Rhizoma and Evodiae Fructus) treats HCC and improves Tex.Methods: To identify HCC-related and Tex-associated targets, two HCC expression microarray datasets were integrated. Targets related to Tex were retrieved from GeneCards and Online Mendelian Inheritance in Man (OMIM) databases. Active compounds in ZJC were screened. A protein-protein interaction (PPI) network of overlapping targets was constructed using STRING to identify core functional modules. To verify the anti-proliferative effect of ZJC on HCC cells, the CCK-8 assay was performed to detect the viability of Hep3B and HepG2.2.15 cells treated with gradient concentrations of ZJC. Western Blot analysis was conducted to measure the protein expression levels of key molecules. Immunohistochemical (IHC) staining was used to assess the proliferation index of tumor cells, the infiltration of immune cells, and the expression of immune-related markers.Results: HCC-related genes, Tex targets, and ZJC targets were identified through bioinformatics analysis, 136 overlapping targets were obtained. ZJC inhibited Hep3B/HepG2.2.15 cell proliferation with IC50 values of 310 μg/mL and 530 μg/mL, respectively. The pathway analysis conducted using DAVID revealed that the intersecting targets were mainly enriched in the mTOR signaling pathway and the transcriptional regulation process. H22 xenografts were treated with ZJC or anti-PD-1 to evaluate tumor growth and immune responses. ZJC suppressed HCC cell proliferation and reduced the expression of Ki67. Mechanistically, it downregulated phosphorylated mTOR (p-mTOR), p-eIF4E, and p-p70S6K, and this downregulated state could be reversed by the restoration of mTOR activators. ZJC reduced the expression of cyclin-dependent kinase 1 (CDK1). In HCC tissues, M1 macrophages were reduced, while M2 macrophages and exhausted T cells were accumulated. ZJC treatment inhibited tumor growth and modulated immune infiltration. Additionally, ZJC and anti-PD-1 promoted the expression or aggregation of CD8-positive cells. In addition, the control group showed relatively high positive staining for CD163, whereas ZJC and anti-PD-1 inhibited the expression or aggregation of CD163-positive cells.Conclusion: ZJC exerts dual anti-tumor effects by inhibiting the mTOR-eIF4E/p70S6K-CDK1 pathway and remodeling the immunosuppressive microenvironment of HCC.
- Open Access
- 17 June 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1598872
Therapeutic interventions aimed at cccDNA: unveiling mechanisms and evaluating the potency of natural products
Hepatitis B virus (HBV) infection persists as a formidable global health predicament, imposing a substantial burden on public health. It not only elevates the risk of cirrhosis but also significantly heightens the incidence of hepatocellular carcinoma (HCC), thereby exacerbating the complexity of managing this disease. Central to the intractability of chronic hepatitis B is the tenacious persistence of covalently closed circular DNA (cccDNA) within the nuclei of infected hepatocytes. This cccDNA serves as a stable transcriptional template, continuously fueling the production of viral components and rendering the virus refractory to current antiviral interventions. The attainment of a definitive cure for HBV infection hinges upon the development of innovative antiviral strategies that can precisely and effectively target and eliminate cccDNA from the infected liver cells. In this regard, natural products have emerged as a promising source of potential therapeutics. This comprehensive review delves into the natural products that have shown promise in specifically targeting cccDNA. It meticulously elucidates the intricate molecular mechanisms through which these natural compounds modulate cccDNA activity, such as interfering with cccDNA formation, disrupting its epigenetic regulation, or inhibiting its transcriptional output. Developing innovative strategies to target and eliminate cccDNA is crucial for curing HBV infection, and natural products hold great promise. This review details several natural products with cccDNA-targeting potential, supported by clear mechanisms and data. Dehydrocheilanthifolin (DHCH) from Corydalis saxicola inhibits HBsAg and HBeAg secretion in HepG2.2.15 cells. It may disrupt viral processes like pgRNA packaging or DNA polymerase activity, with IC50 values for reducing extracellular, intracellular DNA, and cccDNA at 15.08 μM, 7.62 μM, and 8.25 μM respectively. Methyl helicterate from Helicteres angustifolia decreases HBsAg, HBeAg, HBV DNA, and cccDNA in HepG2.2.15 cells. 15.8 μM reduces intracellular cccDNA. Curcumin from turmeric reduces viral load and cccDNA in d-imHCs; 30µM halves cccDNA levels. Epigallocatechin gallate (EGCG) from green tea hinders viral transcription and replication. 22.9μg/ml EGCG lowers cccDNA by about 60%. Asiaticoside from Hydrocotyle sibthorpioides inhibits HBsAg, HBeAg, and cccDNA in HepG2.2.15 cells. Notably, despite extensive research, no natural product has yet obtained clinical validation for cccDNA clearance, highlighting the significant translational gap between pre-clinical research and clinical application. By elucidating these molecular mechanisms, this review aims to contribute to the development of HBV-targeted therapies, offering valuable insights for designing novel therapeutic agents and optimizing existing treatment regimens, ultimately advancing the quest for an effective cure for HBV infection.
- 17 June 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1598872
Open AccessTherapeutic interventions aimed at cccDNA: unveiling mechanisms and evaluating the potency of natural products
Hepatitis B virus (HBV) infection persists as a formidable global health predicament, imposing a substantial burden on public health. It not only elevates the risk of cirrhosis but also significantly heightens the incidence of hepatocellular carcinoma (HCC), thereby exacerbating the complexity of managing this disease. Central to the intractability of chronic hepatitis B is the tenacious persistence of covalently closed circular DNA (cccDNA) within the nuclei of infected hepatocytes. This cccDNA serves as a stable transcriptional template, continuously fueling the production of viral components and rendering the virus refractory to current antiviral interventions. The attainment of a definitive cure for HBV infection hinges upon the development of innovative antiviral strategies that can precisely and effectively target and eliminate cccDNA from the infected liver cells. In this regard, natural products have emerged as a promising source of potential therapeutics. This comprehensive review delves into the natural products that have shown promise in specifically targeting cccDNA. It meticulously elucidates the intricate molecular mechanisms through which these natural compounds modulate cccDNA activity, such as interfering with cccDNA formation, disrupting its epigenetic regulation, or inhibiting its transcriptional output. Developing innovative strategies to target and eliminate cccDNA is crucial for curing HBV infection, and natural products hold great promise. This review details several natural products with cccDNA-targeting potential, supported by clear mechanisms and data. Dehydrocheilanthifolin (DHCH) from Corydalis saxicola inhibits HBsAg and HBeAg secretion in HepG2.2.15 cells. It may disrupt viral processes like pgRNA packaging or DNA polymerase activity, with IC50 values for reducing extracellular, intracellular DNA, and cccDNA at 15.08 μM, 7.62 μM, and 8.25 μM respectively. Methyl helicterate from Helicteres angustifolia decreases HBsAg, HBeAg, HBV DNA, and cccDNA in HepG2.2.15 cells. 15.8 μM reduces intracellular cccDNA. Curcumin from turmeric reduces viral load and cccDNA in d-imHCs; 30µM halves cccDNA levels. Epigallocatechin gallate (EGCG) from green tea hinders viral transcription and replication. 22.9μg/ml EGCG lowers cccDNA by about 60%. Asiaticoside from Hydrocotyle sibthorpioides inhibits HBsAg, HBeAg, and cccDNA in HepG2.2.15 cells. Notably, despite extensive research, no natural product has yet obtained clinical validation for cccDNA clearance, highlighting the significant translational gap between pre-clinical research and clinical application. By elucidating these molecular mechanisms, this review aims to contribute to the development of HBV-targeted therapies, offering valuable insights for designing novel therapeutic agents and optimizing existing treatment regimens, ultimately advancing the quest for an effective cure for HBV infection.
- Open Access
- 27 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1564852
Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease
Background: The global prevalence of non-alcoholic fatty liver disease (NAFLD) has surged, largely driven by modern lifestyle changes and dietary shifts. As these factors profoundly impact human health, exploring effective therapeutic strategies for NAFLD has become a pressing medical concern. Previous studies have suggested that ginsenosides may offer a potential treatment approach for NAFLD by reducing oxidative stress and controlling inflammation. However, its efficacy and safety remain unclear. Therefore, the aim of this systematic review and meta-analysis is to evaluate the role of ginsenosides in the treatment of NAFLD.Methods: We searched for relevant studies published through September 2024, including databases such as PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Data. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) Animal Experiment Bias Risk Assessment Tool was used to evaluate the quality of the literature. Subsequently, Review Manager (RevMan, version 5.3) and STATA 15 software was utilized for data analysis.Results: Finally, 30 studies involving a total of 604 animals were included in the analysis. The results showed that, compared with the model group, ginsenosides significantly reduces total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL), body weight, liver weight, liver index, serum insulin, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6) and NAFLD Activity Score (NAS). Due to the high heterogeneity, we conducted subgroup analyses of the main results ALT, AST, TC and TG by animal strains, modeling methods, administration methods, ginsenoside dosages and types of ginsenosides. The results showed that the heterogeneity of TC may be derived from differences in modeling methods. The results showed that the heterogeneity of TC may be derived from differences in modeling methods.Conclusion: In this study, we summarized the molecular mechanism of ginsenosides in regulating NAFLD, mainly focusing on inhibiting inflammation and oxidative stress, improving insulin sensitivity, and regulating intestinal flora. Preclinical evidence indicates that ginsenosides represent a novel therapeutic avenue for NAFLD. The mechanism of ginsenosides in treating NAFLD may involve anti-inflammation, antioxidation, improving insulin resistance, and regulating intestinal flora. However, the inclusion of studies with low methodological quality and the existence of publication bias may undermine the validity of the results. To fully elucidate the mechanisms underlying the therapeutic effects of ginsenosides, future research should employ more rigorous experimental designs and conduct comprehensive investigations.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/.
- 27 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1564852
Open AccessNovel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease
Background: The global prevalence of non-alcoholic fatty liver disease (NAFLD) has surged, largely driven by modern lifestyle changes and dietary shifts. As these factors profoundly impact human health, exploring effective therapeutic strategies for NAFLD has become a pressing medical concern. Previous studies have suggested that ginsenosides may offer a potential treatment approach for NAFLD by reducing oxidative stress and controlling inflammation. However, its efficacy and safety remain unclear. Therefore, the aim of this systematic review and meta-analysis is to evaluate the role of ginsenosides in the treatment of NAFLD.Methods: We searched for relevant studies published through September 2024, including databases such as PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Data. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) Animal Experiment Bias Risk Assessment Tool was used to evaluate the quality of the literature. Subsequently, Review Manager (RevMan, version 5.3) and STATA 15 software was utilized for data analysis.Results: Finally, 30 studies involving a total of 604 animals were included in the analysis. The results showed that, compared with the model group, ginsenosides significantly reduces total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL), body weight, liver weight, liver index, serum insulin, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6) and NAFLD Activity Score (NAS). Due to the high heterogeneity, we conducted subgroup analyses of the main results ALT, AST, TC and TG by animal strains, modeling methods, administration methods, ginsenoside dosages and types of ginsenosides. The results showed that the heterogeneity of TC may be derived from differences in modeling methods. The results showed that the heterogeneity of TC may be derived from differences in modeling methods.Conclusion: In this study, we summarized the molecular mechanism of ginsenosides in regulating NAFLD, mainly focusing on inhibiting inflammation and oxidative stress, improving insulin sensitivity, and regulating intestinal flora. Preclinical evidence indicates that ginsenosides represent a novel therapeutic avenue for NAFLD. The mechanism of ginsenosides in treating NAFLD may involve anti-inflammation, antioxidation, improving insulin resistance, and regulating intestinal flora. However, the inclusion of studies with low methodological quality and the existence of publication bias may undermine the validity of the results. To fully elucidate the mechanisms underlying the therapeutic effects of ginsenosides, future research should employ more rigorous experimental designs and conduct comprehensive investigations.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/.
- Top Cited Papers
- 5 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 137, 156374
mTOR/HIF-1α pathway-mediated glucose reprogramming and macrophage polarization by Sini decoction plus ginseng soup in ALF
- 5 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 137, 156374
Top Cited PapersmTOR/HIF-1α pathway-mediated glucose reprogramming and macrophage polarization by Sini decoction plus ginseng soup in ALF
- Open Access
- 1 January 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 83-96
A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the major cause of chronic liver disease worldwide, with no universally recognized effective treatments currently available. In recent years, ginseng and its principal active components, such as ginsenosides, have shown potential protective effects in the treatment of these liver diseases. In NAFLD, studies have demonstrated that ginseng can improve hepatic lipid metabolism, reduce inflammatory responses, and inhibit oxidative stress and fibrosis, thereby attenuating the progression of NAFLD. Additionally, ginseng inhibits oxidative stress by scavenging free radicals and enhancing antioxidant enzyme activities, and it can impede fibrosis by interfering with the fibrotic signaling pathways. These combined effects contribute to attenuating the progression of NAFLD. These findings highlight the promise of ginseng as a potential therapeutic candidate for the treatment of NAFLD. However, despite the significant efficacy of ginseng in human NAFLD treatment, the number and quality of clinical studies remain limited, with a lack of large-scale, multicenter clinical trials to confirm these effects. Moreover, the pharmacokinetic properties of different ginsenosides, optimal therapeutic dosages, and the safety of long-term use require further investigation. This review summarizes the existing evidence on the mechanisms of action of ginseng and its active components in human NAFLD, assesses their potential as therapeutic options, and proposes future research directions to provide stronger scientific support for clinical application. Additionally, we performed a network pharmacology analysis of ginseng in relation to NAFLD to identify and investigate potential targets of ginseng in the treatment of NAFLD. This analysis aims to provide a theoretical foundation for the development of ginseng -based drugs for combating NAFLD.
- 1 January 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 83-96
Open AccessA Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the major cause of chronic liver disease worldwide, with no universally recognized effective treatments currently available. In recent years, ginseng and its principal active components, such as ginsenosides, have shown potential protective effects in the treatment of these liver diseases. In NAFLD, studies have demonstrated that ginseng can improve hepatic lipid metabolism, reduce inflammatory responses, and inhibit oxidative stress and fibrosis, thereby attenuating the progression of NAFLD. Additionally, ginseng inhibits oxidative stress by scavenging free radicals and enhancing antioxidant enzyme activities, and it can impede fibrosis by interfering with the fibrotic signaling pathways. These combined effects contribute to attenuating the progression of NAFLD. These findings highlight the promise of ginseng as a potential therapeutic candidate for the treatment of NAFLD. However, despite the significant efficacy of ginseng in human NAFLD treatment, the number and quality of clinical studies remain limited, with a lack of large-scale, multicenter clinical trials to confirm these effects. Moreover, the pharmacokinetic properties of different ginsenosides, optimal therapeutic dosages, and the safety of long-term use require further investigation. This review summarizes the existing evidence on the mechanisms of action of ginseng and its active components in human NAFLD, assesses their potential as therapeutic options, and proposes future research directions to provide stronger scientific support for clinical application. Additionally, we performed a network pharmacology analysis of ginseng in relation to NAFLD to identify and investigate potential targets of ginseng in the treatment of NAFLD. This analysis aims to provide a theoretical foundation for the development of ginseng -based drugs for combating NAFLD.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9665-9681
Targeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy
Cholangiocarcinoma (CCA) is a highly aggressive and poorly prognostic tumor. Due to the lack of early symptoms, diagnosing CCA remains challenging, often occurring at an advanced stage. Therefore, exploring the underlying mechanisms of CCA development and identifying potential biomarkers and therapeutic targets is crucial. Recently, metabolic reprogramming in cancer cells has emerged as a hallmark of the disease. Glycolysis has been identified as a central component of metabolic reprogramming in CCA, with multiple signaling pathways and key enzymes playing significant roles. Additionally, non-coding RNAs (ncRNAs) and post-translational modifications of proteins are also involved in regulating glycolysis in CCA. In this review, we provide a comprehensive summary of the alterations in cancer metabolism and the diverse signaling pathways involved, as they might exert an impact on the development of CCA. Overall, targeting glycolysis holds considerable promise as a crucial strategy for enhancing the therapeutic outcomes of CCA. In addition, we performed a bioinformatic analysis of the relationship between CCA and glycolysis to identify and investigate potential targets. The purpose of this study is to provide a theoretical basis for the development of CCA targets.
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9665-9681
Open AccessTargeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy
Cholangiocarcinoma (CCA) is a highly aggressive and poorly prognostic tumor. Due to the lack of early symptoms, diagnosing CCA remains challenging, often occurring at an advanced stage. Therefore, exploring the underlying mechanisms of CCA development and identifying potential biomarkers and therapeutic targets is crucial. Recently, metabolic reprogramming in cancer cells has emerged as a hallmark of the disease. Glycolysis has been identified as a central component of metabolic reprogramming in CCA, with multiple signaling pathways and key enzymes playing significant roles. Additionally, non-coding RNAs (ncRNAs) and post-translational modifications of proteins are also involved in regulating glycolysis in CCA. In this review, we provide a comprehensive summary of the alterations in cancer metabolism and the diverse signaling pathways involved, as they might exert an impact on the development of CCA. Overall, targeting glycolysis holds considerable promise as a crucial strategy for enhancing the therapeutic outcomes of CCA. In addition, we performed a bioinformatic analysis of the relationship between CCA and glycolysis to identify and investigate potential targets. The purpose of this study is to provide a theoretical basis for the development of CCA targets.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 8429-8443
Biological Roles and Clinical Therapeutic Applications of Tumor-Associated Macrophages in Colorectal Liver Metastasis
Colorectal cancer (CRC) commonly metastasizes to the liver, and this poses a significant clinical challenge. Tumor-associated macrophages (TAMs), key players within the TME, play a significant role in promoting CRC metastasis by secreting various chemokines, growth factors, and cytokines. This review not only aims to enhance our knowledge of TAMs’ functions in CRC progression and metastasis but also examines innovative therapeutic strategies to address the clinical problem of colorectal liver metastasis (CLM). By targeting TAMs, we may be able to develop more effective treatments and offer hope to patients suffering from this devastating disease.
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 8429-8443
Open AccessBiological Roles and Clinical Therapeutic Applications of Tumor-Associated Macrophages in Colorectal Liver Metastasis
Colorectal cancer (CRC) commonly metastasizes to the liver, and this poses a significant clinical challenge. Tumor-associated macrophages (TAMs), key players within the TME, play a significant role in promoting CRC metastasis by secreting various chemokines, growth factors, and cytokines. This review not only aims to enhance our knowledge of TAMs’ functions in CRC progression and metastasis but also examines innovative therapeutic strategies to address the clinical problem of colorectal liver metastasis (CLM). By targeting TAMs, we may be able to develop more effective treatments and offer hope to patients suffering from this devastating disease.
- Open Access
- 28 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 25705
Expression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis of hepatocellular carcinoma
The online version contains supplementary material available at 10.1038/s41598-024-76578-5.
- 28 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 25705
Open AccessExpression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis of hepatocellular carcinoma
The online version contains supplementary material available at 10.1038/s41598-024-76578-5.